CYP19A1 and polycystic ovary syndrome: Overall, these data provide strong confirmation that myo-Ins and D-Chiro-Ins in the ratio of 40:1 at pharmacological concentrations down-regulate some androgenic enzymes (HSD3B) while re-establishing a physiological response of CYP19A1 and FSHR, thus overcoming the main steroidogenic abnormalities found in PCOS.